Felix chief executive officer Kyle Zien wrote in a statement to The Globe that the ad was published in error and that its removal demonstrated the efficacy of our review and audit processes. Ahmad Elkalza, CEO of Jills parent company, said his team reviewed the Latisse ad and paused it
A different type of diabetes mellitus medication might be the solution for you if youve tried other treatment strategies, have spoken with a urologist or PFPT, and are still experiencing symptoms of incontinence
This "dual agonist" mimics the gut peptides glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
Saxenda a higher-dose daily liraglutide formulation Wegovy a higher-dose weekly semaglutide formulation Zepbound the weight-loss formulation of tirzepatide These medications are typically approved for adults with obesity, or for those who are overweight with additional health conditions such as high blood pressure, abnormal cholesterol, or sleep apnoea

Combining with other weight loss agents Tesofensine + GLP-1 agonists (theoretical): Different mechanisms = potential synergy Tesofensine: Metabolic + CNS appetite GLP-1s : Strong appetite + gastric slowing Could enhance weight loss to 20-25%+ BUT: No clinical data, significant risks Not recommended without supervision Potential combination benefits: Address multiple pathways Overcome plateaus Better than either alone (theoretically) Metabolic boost + strong appetite suppression Maximum fat loss Combination risks: Compounded cardiovascular strain Unknown drug interactions Excessive weight loss risks Cost ($1,500-2,000/month) Safer alternatives to tesofensine combinations: Tirzepatide alone (15-22% loss, FDA approved) CagriSema (sema + cagrilintide, 15-25%) GLP-1 + lifestyle (safer, proven) Learn about peptide stacking strategies at SeekPeptides
Hou, J., Lages, N